Company / SG&A Expense
Collegium Pharmaceutical, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$284.8M
FY2025
5-year range
$119.0M / $284.8M
FY2021-FY2025
Trend
+35.4%
vs FY2024
Sector context
#56 of 213
Health Care
What the data says
At $285M, Collegium Pharmaceutical, Inc.'s sg&a expense ranks #158 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $19M in FY2017 to $285M in FY2025.
Based on SEC 10-K filings.
$285M in FY2025 with a 5-year CAGR of +20.1%.
Increased from $159M to $285M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +18.3%
- 5-Year CAGR
- +20.1%
- 10-Year CAGR
- -
Sector benchmark
#158 of 213 in Health CareTop 74% of 213This company $284.8M Sector average $722.3M
▼
-60.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 35.4% year-over-year.
- Ranks #56 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $284.8M | +35.4% |
| FY2024 | $210.4M | +32.1% |
| FY2023 | $159.2M | -7.5% |
| FY2022 | $172.2M | +44.7% |
| FY2021 | $119.0M | +4.5% |
| FY2020 | $113.8M | -2.2% |
| FY2019 | $116.4M | -8.1% |
| FY2018 | $126.8M | +569.6% |
| FY2017 | $18.9M | -76.5% |
| FY2016 | $80.6M | +325.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026